A parallel-group comparison study of celecoxib with loxoprofen sodium in third mandibular molar extraction patients

Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely, but they may damage the upper gastrointestinal mucosa owing to their mechanism of action. Selective cyclooxygenase 2 (COX-2) inhibitors are known to have a reduced risk for such damage. In this comparative study, the efficacy a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of oral and maxillofacial surgery 2014-12, Vol.43 (12), p.1509-1513
Main Authors: Yamashita, Y, Sano, N, Shimohira, D, Danjo, A, Goto, M
Format: Article
Language:English
Subjects:
Adult
Aged
analgesic effect
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Celecoxib
Cyclooxygenase 2 Inhibitors - therapeutic use
Dentistry
Female
Humans
loxoprofen sodium
Male
Mandible - surgery
Middle Aged
Molar, Third - surgery
non-steroidal anti-inflammatory drugs
Pain Measurement
Pain, Postoperative - drug therapy
Phenylpropionates - therapeutic use
post-exodontic pain
Pyrazoles - therapeutic use
Sulfonamides - therapeutic use
Surgery
Surveys and Questionnaires
Tooth Extraction
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely, but they may damage the upper gastrointestinal mucosa owing to their mechanism of action. Selective cyclooxygenase 2 (COX-2) inhibitors are known to have a reduced risk for such damage. In this comparative study, the efficacy and safety of the selective COX-2 inhibitor celecoxib for pain after third mandibular molar extraction were compared with those of loxoprofen sodium. This was a parallel-group comparison study; 107 patients who had undergone third mandibular molar extraction were given celecoxib and 102 were given loxoprofen. The level of pain on a visual analogue scale (VAS) 15 min and 30 min after taking the experimental drug decreased over time, with no significant difference between the two groups. The percentage of patients taking a second dose was 64.5% for celecoxib and 80.4% for loxoprofen. The time to second dose was significantly longer for celecoxib (533.5 min) than for loxoprofen (387.4 min). There was no significant difference in the patients’ impression of efficacy between the two groups, with ratings of ‘excellent’ and ‘good’ for 77.4% in the loxoprofen group and 74.5% in the celecoxib group. These results demonstrate that celecoxib is of equal clinical value to loxoprofen for acute pain after third mandibular molar extraction.
ISSN:0901-5027
1399-0020
DOI:10.1016/j.ijom.2014.09.002